Address
Mailpoint 810
Southampton, SO16 6YD
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 23 8051 2800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
36
First IPO Date
October 26, 2004
| Name | Title | Pay | Year Born |
| Richard Marsden | Chief Executive Officer, MD & Executive Director | 328,000 | 1967 |
| Donna Davies | Co-Founder & Member of Scientific Advisory Board | 40,000 | N/A |
| Ratko Djukanovic | Co-Founder & Member of Scientific Advisory Board | 40,000 | N/A |
| Stephen T. Holgate | Co-Founder & Member of Scientific Advisory Board | 40,000 | 1947 |
| Joseph Tregonning Colliver | Chief Financial Officer & Executive Director | 197,410 | 1980 |
| Marcin Mankowski | Chief Medical Officer | 0 | N/A |
| Victoria Tear | Head of Laboratory | 0 | N/A |
| Richard Francis | Senior Vice President and Head of CMC & Quality | 0 | N/A |
| Simon William Holden | Company Secretary | 0 | 1976 |
| Jody Brookes | Senior Vice President & Head of Clinical Operations | 0 | N/A |
| Gareth E. Walters | Chief Regulatory Officer | 0 | 1959 |
Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.